Jim Cramer: Buy Phillips-Van Heusen, HCI Group, and These 2 Stocks
Jim Cramer made the following calls on September 9th, 2013. What do you think about his picks?
Phillips-Van Heusen Corp. (NYSE:PVH): Jim Cramer ranked this stock a Buy. Cramer previously ranked this stock a Buy on September 6, 2013. The stock’s 52-week high is $134.98, and its 52-week low is $90.15. Cramer talked with Manny Chirico, the CEO of Calvin Klein owner Phillips-Van Heusen. Chirico noted that third quarter numbers were particularly volatile, but that he expected fourth quarter results to be solid during the holiday season. He also pointed out that the slow economic turnaround in Spain and Italy has hurt sales, as the company’s sales numbers have really only turned around in northern Europe as opposed to southern Europe.
HCI Group Inc. (NYSE:HCI): Jim Cramer ranked this stock a Buy. The stock’s 52-week high is $37.94, and its 52-week low is $18.29. Cramer said that he likes HCI, an insurer of homeowners, because they’re inexpensive on their book value. The stock jumped sharply near the start of this month after they assumed a group of over 50,000 policies from the state of Florida.
Primerica, Inc. (NYSE:PRI): Jim Cramer ranked this stock a Buy. Cramer previously ranked this stock a Buy on April 24, 2013. The stock’s 52-week high is $42.37, and its 52-week low is $27.22. Cramer claims that Primerica is a good company for longer term investment. Last week, the company announced that it would be incorporating FireLight software into its process for annuity applications.
Seattle Genetics Inc. (NASDAQ:SGEN): Jim Cramer ranked this stock a Buy. Cramer previously ranked this stock a Buy on August 27, 2013. The stock’s 52-week high is $46.00, and its 52-week low is $21.05. Cramer talked with Clay Siegall, the founder and CEO of Seattle Genetics, who stressed that the company is making real progress towards saving lives by developing new drugs to treat cancer. Siegall cited trial results that showed a drastic improvement in survival rates for T-cell lymphoma, also claiming that Seattle Genetics’s drugs can lead to better results for patients because they have fewer side effects. Siegall also stated that Seattle’s many partnerships played a key role in its success in the industry. The stock has nearly doubled in value since the start of 2013.
Don’t Miss: Another Dreamliner Hiccup Doesn’t Faze Boeing.